Novo Nordisk Faces a Two-Pronged Test: Quarterly Results and a Pivotal FDA Decision
The Danish pharmaceutical giant Novo Nordisk enters a defining stretch this week, with its second-quarter earnings due on…
Novo Nordisk’s Two-Pronged Catalyst: An Analyst Upgrade and a €69 Million Research Bet
Novo Nordisk closed the week with a 3.21% gain, pushing its shares to €38.90 on Friday. The rally…